Joshua I Barzilay1, Barry R Davis2, Sara L Pressel2, Alokananda Ghosh2, Mahboob Rahman3, Paula T Einhorn4, William C Cushman5, Paul K Whelton6, Jackson T Wright7. 1. Division of Endocrinology, Kaiser Permanente of Georgia, and the Division of Endocrinology, Emory University School of Medicine, Atlanta, Georgia, USA. 2. Coordinating Center for Clinical Trials, The University of Texas School of Public Health, Houston, Texas, USA. 3. Division of Nephrology, University Hospitals Case Western Reserve University, Cleveland, Ohio, USA. 4. Division of Cardiovascular Sciences, National Heart, Lung, and Blood Institute, Bethesda, Maryland, USA. 5. Preventive Medicine Section, Veterans Affairs Medical Center, Memphis, Tennessee, USA. 6. Department of Epidemiology, School of Public Health and Tropical Medicine, Tulane University, New Orleans, Louisiana, USA. 7. Division of Nephrology and Hypertension, Case Western Reserve University, University Hospitals Case Medical Center, Louis Stokes Cleveland Veterans Affairs Medical Center, Cleveland, Ohio, USA.
Abstract
BACKGROUND:Impaired renal function is a risk factor for cardiovascular disease, end-stage renal disease (ESRD), and mortality. The impact of short-term renal function decline on outcomes is less well studied. The association of antihypertensive medications with the impact of short-term estimated glomerular filtration rate (eGFR) decline is not known. METHODS: We examined 20,207 hypertensive participants with baseline and 2-year creatinine levels from which eGFR changes were estimated. The associations between eGFR change with incident coronary heart disease (CHD), stroke, heart failure (HF), all-cause mortality, and ESRD during 2.9 years of in-trial follow up, and with mortality during in-trial and post-trial follow-up (7.6 years), were studied. Results were assessed by primary hypertension (HTN) treatment (chlorthalidone, lisinopril, and amlodipine) and adjusted for baseline eGFR levels. RESULTS: In the short run, an eGFR decline below the cohort median (-1.28 ml/minute/1.73 m2/2 years) vs. above the median, or a 5 ml/min/1.73 m2/year decline vs. no decline, was associated with significant hazard risk for CHD (1.06-1.28), HF (1.24-1.91), ESRD (2.84-6.01), and mortality (1.08-1.19), but not with stroke risk. In the long term, there was a significant association with mortality (1.11-1.34). Interaction terms for outcomes by antihypertensive treatments were not statistically significant except for ESRD between amlodipine vs. chlorthalidone (hazard ratio: 3.17 [2.59, 3.88] vs. 2.41 [1.98, 2.97]; P interaction = 0.005) for a 5 ml/min/1.73 m2/year eGFR decline. CONCLUSION: Decline in eGFR over 2 years is associated with increased risk of clinical outcomes beyond the effects of baseline eGFR. These risks were the same irrespective of the primary medication used to treat HTN.
RCT Entities:
BACKGROUND: Impaired renal function is a risk factor for cardiovascular disease, end-stage renal disease (ESRD), and mortality. The impact of short-term renal function decline on outcomes is less well studied. The association of antihypertensive medications with the impact of short-term estimated glomerular filtration rate (eGFR) decline is not known. METHODS: We examined 20,207 hypertensiveparticipants with baseline and 2-year creatinine levels from which eGFR changes were estimated. The associations between eGFR change with incident coronary heart disease (CHD), stroke, heart failure (HF), all-cause mortality, and ESRD during 2.9 years of in-trial follow up, and with mortality during in-trial and post-trial follow-up (7.6 years), were studied. Results were assessed by primary hypertension (HTN) treatment (chlorthalidone, lisinopril, and amlodipine) and adjusted for baseline eGFR levels. RESULTS: In the short run, an eGFR decline below the cohort median (-1.28 ml/minute/1.73 m2/2 years) vs. above the median, or a 5 ml/min/1.73 m2/year decline vs. no decline, was associated with significant hazard risk for CHD (1.06-1.28), HF (1.24-1.91), ESRD (2.84-6.01), and mortality (1.08-1.19), but not with stroke risk. In the long term, there was a significant association with mortality (1.11-1.34). Interaction terms for outcomes by antihypertensive treatments were not statistically significant except for ESRD between amlodipine vs. chlorthalidone (hazard ratio: 3.17 [2.59, 3.88] vs. 2.41 [1.98, 2.97]; P interaction = 0.005) for a 5 ml/min/1.73 m2/year eGFR decline. CONCLUSION: Decline in eGFR over 2 years is associated with increased risk of clinical outcomes beyond the effects of baseline eGFR. These risks were the same irrespective of the primary medication used to treat HTN.
Authors: Hicham Skali; Hajime Uno; Andrew S Levey; Lesley A Inker; Marc A Pfeffer; Scott D Solomon Journal: Am Heart J Date: 2011-08-09 Impact factor: 4.749
Authors: B R Davis; J A Cutler; D J Gordon; C D Furberg; J T Wright; W C Cushman; R H Grimm; J LaRosa; P K Whelton; H M Perry; M H Alderman; C E Ford; S Oparil; C Francis; M Proschan; S Pressel; H R Black; C M Hawkins Journal: Am J Hypertens Date: 1996-04 Impact factor: 2.689
Authors: Robert M Perkins; Ion D Bucaloiu; H Lester Kirchner; Nasrin Ashouian; James E Hartle; Taher Yahya Journal: Clin J Am Soc Nephrol Date: 2011-06-16 Impact factor: 8.237
Authors: Mahboob Rahman; Sara Pressel; Barry R Davis; Chuke Nwachuku; Jackson T Wright; Paul K Whelton; Joshua Barzilay; Vecihi Batuman; John H Eckfeldt; Michael Farber; Mario Henriquez; Nelson Kopyt; Gail T Louis; Mohammad Saklayen; Carol Stanford; Candace Walworth; Harry Ward; Thomas Wiegmann Journal: Arch Intern Med Date: 2005-04-25
Authors: Tanvir C Turin; Min Jun; Matthew T James; Marcello Tonelli; Joseph Coresh; Braden J Manns; Brenda R Hemmelgarn Journal: Int J Cardiol Date: 2015-09-28 Impact factor: 4.164
Authors: Caroline S Fox; Kunihiro Matsushita; Mark Woodward; Henk J G Bilo; John Chalmers; Hiddo J Lambers Heerspink; Brian J Lee; Robert M Perkins; Peter Rossing; Toshimi Sairenchi; Marcello Tonelli; Joseph A Vassalotti; Kazumasa Yamagishi; Josef Coresh; Paul E de Jong; Chi-Pang Wen; Robert G Nelson Journal: Lancet Date: 2012-09-24 Impact factor: 79.321
Authors: Israel Berger; Sunny Wu; Philip Masson; Patrick J Kelly; Fiona A Duthie; William Whiteley; Daniel Parker; David Gillespie; Angela C Webster Journal: BMC Med Date: 2016-12-14 Impact factor: 8.775